Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PCSK9-IN-10, a potent and orally active inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), exhibits a half-maximal inhibitory concentration (IC50) of 6.4 µM. By enhancing the expression of Low-Density Lipoprotein Receptor (LDLR) protein and reducing PCSK9 expression, PCSK9-IN-10 effectively decreases atherosclerosis progression. This compound holds promise for hyperlipidemia research applications.
説明 | PCSK9-IN-10, a potent and orally active inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), exhibits a half-maximal inhibitory concentration (IC50) of 6.4 µM. By enhancing the expression of Low-Density Lipoprotein Receptor (LDLR) protein and reducing PCSK9 expression, PCSK9-IN-10 effectively decreases atherosclerosis progression. This compound holds promise for hyperlipidemia research applications. |
ターゲット&IC50 | PCSK9:6.4 µM |
In vitro | PCSK9-IN-10 (0, 2.5, 5, 12.5, 25 µM ; 24 h) significantly reduces PCSK9 protein expression and increases the expression of LDL receptor (LDLR) in a dose-dependent manner.[1] |
In vivo | PCSK9-IN-10 (30 mg/kg ; oral administration ; once daily for 8 weeks) reduces total cholesterol (TC) levels and the size of atherosclerotic plaques in ApoE KO mice.[1] |
分子量 | 373.41 |
分子式 | C18H23N5O4 |
CAS No. | 368434-98-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 225.0 mg/mL (602.6 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PCSK9-IN-10 368434-98-4 Cell Cycle/Checkpoint Metabolism Serine/threonin kinase PCSK9IN10 Inhibitor inhibitor inhibit